INTRODUCTION
============

Identifying patients with multifocal renal cell carcinoma (RCC) is of major importance due to its influence on the treatment strategy, timing, and treatment modality used in such patients. Management of multifocal RCC has been a source of multiple debates for several reasons. First of all, it remains one of the relative contraindications to partial nephrectomy ([@B7]) as it causes many urologists to think twice before embarking on a nephron-sparing approach, either due to technical considerations or oncologic concerns ([@B38]). Second, radical nephrectomy would prevent the patient from potentially requiring a future repeat renal surgery for new or recurrent lesions in the same renal unit; a procedure known to be technically challenging. Third, in the absence of specific genetic studies to identify the clonal origin of every lesion, some may feel uncomfortable assigning ipsilateral or contralateral recurrences as *de novo* satellite tumors rather than intra-renal metastases. Finally, the relative paucity of reported outcomes for patients treated for multifocal RCC has not allowed for a wide acceptance of the nephron-sparing approaches as a preferred treatment modality.

Multifocal RCC has been reported in 5--25% of cases in the world literature ([@B18]; [@B41]). This incongruent variability in values is likely due to a variety of reasons. First, some of those studies have not excluded all patients with hereditary or familial RCC, known to be multifocal in nature ([@B10]; [@B19]; [@B22]; [@B32]). Second the quality of imaging modalities as well as radiologic evaluation used in different eras or locations may have contributed to the variability in detection of multifocal RCC found by different groups ([@B33]). Third, the pathological assessment of specimens has also varied in the different reports. Some investigators examined the renal surface only, others examined the kidney after stripping its capsule, while others examined the kidneys after they had been serially sectioned. Finally, the absence of accepted criteria used to define multifocality may have also resulted in variations of the estimated prevalence of multifocal RCC in the literature.

In the present report, we aim to examine differences in multifocality definitions and detection strategies used in published studies to identify the prevalence of "sporadic" multifocal RCC. We also examine oncologic outcomes of surgeries for sporadic multifocal RCC.

METHODS {#s1}
=======

SYSTEMATIC REVIEW OF THE LITERATURE
-----------------------------------

A PubMed search of the literature was performed independently by each author for articles in the English language using the following terms for the query: "multifocal RCC," "multifocality and RCC," "multicentric RCC," or "bilateral RCC." The references of the published articles were also reviewed for additional publications. We excluded articles that did not specifically exclude patients with familial RCC or known hereditary renal cancer syndromes, and those articles in which the prevalence for multifocal RCC could not be determined. After applying our exclusion criteria, nine articles were selected and these form the basis for the current analysis. The oncologic outcomes were then tabulated from the articles that met our inclusion criteria. Inclusion and exclusion criteria were decided before the literature search was initiated.

For the purpose of this study, multifocality was defined as the presence of two or more tumors present in the same renal unit, regardless of histology or timing of detection in the absence of extra-renal metastatic disease. The prevalence of multifocal RCC was calculated using weighted averages after dividing the number of cases with multifocality by the number of total cases with RCC (solitary and multifocal RCC).

RESULTS
=======

The prevalence of non-hereditary sporadic multifocal RCC was calculated to be 6.8% (**Table [1](#T1){ref-type="table"}**). The occurrence of bilateral multifocal tumors was found to be 11.7%. As shown in **Table [2](#T2){ref-type="table"}**, a subset analysis of our cohort shows that metastasis-free survival and overall-survival are similar to those reported by other series (**Table [3](#T3){ref-type="table"}**). Furthermore, oncologic outcomes are similar for patients treated for solitary as well as for multifocal tumors (in sporadic population). Finally, **Table [3](#T3){ref-type="table"}** shows excellent renal functional preservation in the setting of multiple surgeries on the same renal unit (in hereditary population).

###### 

List of peer reviewed articles included for analysis.

  Reference   Serial section?   Total cases   Total multifocal    RN (%)        PN (%)        Ipsilateral multifocal (%)   Bilateral multifocal (%)
  ----------- ----------------- ------------- ------------------- ------------- ------------- ---------------------------- --------------------------
  [@B37]      Yes               560           81 (14.4%)          560           0             81 (14.4%)                   n/a
  [@B9]       n/a               1113          60 (5.4%)           599 (53.8%)   514 (46.2%)   60 (5.4%)                    8/37 (21%)
  [@B21]      n/a               140           n/a                 114 (81.4%)   26 (19.6%)    n/a                          11 (7.85%)
  [@B27]      Yes               1071          57 (5.3%)           1071          0             57 (5.3%)                    28 (2.6%)
  [@B11]      n/a               2373          130 (5.4%)          2373          0             130 (5.4%)                   n/a
  [@B3]       Yes               40            4 (10%)             40            0             4 (10%)                      n/a
  [@B18]      Yes               124           23 (18.5%)          124           0             23 (18.5%)                   n/a
  [@B25]      Yes               108           7 (6.5%)            108           0             7 (6.5%)                     n/a
  [@B40]      Yes               44            11 (25%)            44            0             11 (6.5%)                    n/a
                                              Weighted average:                               Weighted average:            Weighted average:
                                              6.82%                                           6.82%                        11.72%

###### 

Oncologic outcomes for the study cohort.

  Reference   Number of cases   Number of multifocal kidneys   Median follow-up (year)   Metastasis-free survival at 5 years (%)   Cancer-specific survival at 5 years (%)   Overall-survival at 5 years (%)   Contralateral tumor-free survival at 5 years (%)                        
  ----------- ----------------- ------------------------------ ------------------------- ----------------------------------------- ----------------------------------------- --------------------------------- -------------------------------------------------- ------ ------ ------ ------
  [@B9]       1113              60                             6.1                       97.6                                      96.5                                      98.7                              96.2                                               84.4   84     99.1   94.4
  [@B21]      140               140                            6.1                       n/a                                       n/a                                       n/a                               90.5 (95.8 if NSS)[\*](#fn01){ref-type="fn"}       n/a    n/a    n/a    n/a
  [@B27]      1071              57                             3.4                       73.2                                      71.5                                      n/a                               n/a                                                79.3   75.2   84.9   82.5

n/a, not available.

CCS at 5 years for cases treated with radical nephrectomy or nephron-sparing surgery are 90.5 and 95.8%, respectively.

###### 

Functional outcomes post-nephron-sparing techniques in hereditary multifocal RCC.

  Reference   Number   Median follow-   Change in serum
  ----------- -------- ---------------- -----------------
  [@B5]       13       25               +0.2
  [@B16]      51       56               +0.19
  [@B13]      62       30               +0.01
  [@B23]      25       60               +0.2

DISCUSSION
==========

We found that the prevalence of sporadic multifocal RCC was 6.8% (**Table [1](#T1){ref-type="table"}**). This number is intriguing as the 6.8% rate of multifocality found in this study correlates well with the historic incidence of ipsilateral recurrence after partial nephrectomy of 4--9% ([@B18]; [@B8]; [@B26]). This appears to suggest that many of the lesions that have been considered recurrences or intra-renal metastasis in the past might have just been incipient multifocal lesions not identified pre-operatively or during the actual surgical procedure. Notably, many studies have shown that most satellite lesions, in excess of 60%, are not detected by modern pre-operative imaging studies ([@B1]; [@B9]; [@B21]).

DEFINING MULTIFOCAL RCC
-----------------------

One of the major problems in the study of multifocal RCC is precisely how to define multifocality itself. What defines a multifocal tumor? Is it simply the presence of another lesion within the same renal unit ([@B24]; [@B17])? Must the second lesion by necessity be malignant? Must there be a minimum amount of parenchyma in between primary and satellite lesions in order for multifocality to exist ([@B32])? Must all lesions share the same histology? Does the presence of a contralateral tumor also define multifocal disease ([@B2])? Does the contralateral kidney need to contain multiple tumors for it to be multifocal? And is the multifocality on one kidney related to the multifocality on the opposite kidney? Furthermore, how can we even know if a second lesion within the same renal unit, or on the contralateral kidney for that matter, is a new *de novo* lesion unrelated to the primary tumor, or a local recurrence or metastasis from the primary lesion?

Unfortunately, without performing a specific genetic study designed to evaluate the clonal origin of each mass found it is often difficult to determine whether a second renal lesion implies that patients have multifocal, recurrent, or metastatic disease ([@B24]; [@B17]; [@B4]). Because of our inability to answer these questions, in the present study, we defined multifocality in a broad manner in order to incorporate all the data available to us. Thus, we defined multifocality as the presence of two or more tumors present in the same renal, regardless of histology or timing of detection, in the absence of extra-renal metastatic disease in patients not known to have familial disease or hereditary syndromes. We acknowledge that some patients in our study may nevertheless be part of obscure or yet-to-be-discovered RCC syndromes. This is because the diagnosis of hereditary or familial RCC is not always straight forward and while certain syndromes are well know to all urologists, others, such as familial renal syndromes seen in patients with tuberous sclerosis or succinate dehydrogenase deficiency, for example, are not. In terms of histology, from our earlier studies of hereditary renal tumors we know that multiple tumors of various histologies can coexist within the same renal unit. We also know that the same genetic abnormality can lead to both benign and malignant renal lesions within the same kidney and that these lesions can also be found bilaterally and metachronously. For example, patients with von Hippel--Lindau (VHL) syndrome are prone to develop bilateral multifocal recurrent clear cell RCC; patients with hereditary papillary RCC (HPRCC) develop bilateral papillary type 1 RCC; hereditary leiomyomatosis RCC (HLRCC) patients tend to form aggressive papillary type 2 RCC and Birt--Hogg--Dubé (BHD) patients may develop a whole spectrum of tumors from benign oncocytomas to chromophobe RCC to aggressive clear cell RCC ([@B36]). Furthermore, as our knowledge of the genetic basis of renal neoplasias grows we keep finding new types of hereditary syndromes, such as the less well understood syndromes of tuberous sclerosis and succinate dehydrogenase B deficiency ([@B35]).

HISTORICAL PERSPECTIVE AND CURRENT APPROACH TO MULTIFOCAL RCC
-------------------------------------------------------------

Ever since Robson's 1969 article ([@B28]) suggested that radical nephrectomy should be the treatment of choice for patients with renal tumors, that practice has become standard of care, in particular for kidneys harboring multifocal RCC. Of note, [@B28] conclusion was based on a report of outcomes of a few selected patients. During the next 30--40 years, in large part due to the knowledge gained through patients who underwent partial nephrectomies for imperative indications, Robson's model has come under question. Initial reports about the technical feasibility of nephron-sparing procedures performed for small renal masses and subsequent reports of its oncologic efficacy, similar to that of radical nephrectomy, have slowly built a foundation for a wider utilization of partial nephrectomy ([@B31]). Additionally, with the understanding that RCC was not a single entity but a conglomeration of neoplastic processes, each with its own biological identity and aggressiveness ([@B20]), the field of urology has slowly realized that perhaps a one-operation-fits-all model was not the best way to approach every type of renal tumor. Thus, the indications for elective partial nephrectomy began to expand ([@B31]), resulting in a much larger cohort of cases to be analyzed and compared to outcomes of radical nephrectomy.

We now know that, despite previous teachings, not only tumors smaller than 4 cm but also larger than 4 cm are amenable to nephron-sparing techniques ([@B30]). We also know that stage-by-stage the oncologic outcomes seem to be similar between partial nephrectomy and radical nephrectomy cohorts ([@B5]; [@B16]; [@B6]; [@B23]). Furthermore, recent data have confirmed that patients undergoing radical nephrectomies for RCC are at higher risk not only of developing renal insufficiency ([@B15]; [@B34]) but more ominously, to die of non-cancer-related causes, such as cardiovascular events, compared to patients undergoing nephron-sparing techniques ([@B14]). Additionally, data from patients treated with multiple partial nephrectomies for hereditary and familial RCC syndromes indicate that the oncologic outcome is not altered in those patients when they undergo multiple repeated partial nephrectomies ([@B12]). Finally, National Cancer Institute data on repeat surgical interventions on a same kidney indicate that kidneys can withstand multiple injuries due to surgical procedures and renal function is usually well-preserved (**Table [3](#T3){ref-type="table"}**), preventing patients from having to undergo dialysis or renal transplantation ([@B5]; [@B12]).

Despite all this information, indications for partial nephrectomy still need to be enumerated and radical nephrectomies are still favored by a large number of urologists even for small solitary renal tumors of less than 4 cm in maximum diameter ([@B29]). In fact, at the present time there are no NCCN Guidelines regarding multifocal RCC tumors. Perhaps a better treatment approach for sporadic multifocal RCC would be performing the same type of surgery as for patients with familial or hereditary RCC syndromes, i.e., resection of all detectable renal lesions via nephron-sparing techniques as they become apparent and reach a certain size ([@B39]). The latter is supported by the fact that: (a) there is no oncologic benefit to performing radical nephrectomy versus partial nephrectomy, (b) there are no data proving that newly discovered post-surgical lesions are indeed recurrences or metastases after partial nephrectomy, (c) at least 20% of RCC lesions are either benign or indolent in nature, and (d) the data showing that losing a renal unit puts patients at higher risk not only of developing renal insufficiency but also of death from non-cancer-related causes ([@B8]). Finally, as the data presented in this study show, a significant number of patients with multifocal RCC will have renal lesions in the contralateral kidney, possibly necessitating surgery at a later date, increasing their chances of becoming anephric, had radical nephrectomy previously performed.

CLINICAL IMPLICATIONS
---------------------

Identifying patients at higher risk for metastatic disease and those who are likely to fail local therapy is indeed of paramount importance. Nevertheless, treating patients with overkill surgeries under the presumption that more is better puts patients at risk not only for renal insufficiency but also for cardiovascular disease and death from non-cancer-related causes ([@B34]; [@B14]). Radical nephrectomy may not only be unnecessary in these patients but it may also prevent those patients from future treatments (e.g., targeted therapies) that require a normal renal function to qualify for them. Although we strongly advocate appropriate surgery for local control of renal lesions, with negative surgical margins, the reader should also be aware of recent data showing that positive surgical margins do not jeopardize survival outcomes in patients undergoing nephron-sparing techniques ([@B42]). Therefore, we encourage surgeons to attempt nephron-sparing surgery whenever technically feasible and, in cases of multifocal disease.

LIMITATIONS OF THE STUDY
------------------------

The present study has several limitations. It is possible that some of the patients included in our analysis were undiagnosed hereditary RCC cases. We only reported results on patients treated surgically and may have potentially missed those with metastatic disease that were not included in the original publications.

CONCLUSION
==========

Multifocal RCC remains an underappreciated and misunderstood entity with a prevalence of at least 6%. Bilateral multifocal disease is found in 11.7% of cases. The presence of multiple renal tumors in one kidney appears to increase the risk of having renal lesions in the contralateral kidney. Twenty percent of multifocal RCC are benign or indolent in nature. Stage-by-stage, oncologic outcome appears similar for patients treated with radical or partial nephrectomy. Resection of multiple renal lesions from the same renal unit in a single setting is feasible and may allow for excellent preservation renal function. Radical nephrectomy, in the context of RCC, appears to increase the risk of renal insufficiency and death from unrelated causes. Nephron-sparing techniques should thus be considered whenever technically feasible, in particular in cases of multifocal RCC.
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